Nebu-Flow, a Glasgow, Scotland, UK-based provider of a nebulizer platform, raised additional $5.9M in funding.
The round was led by SCVC, and was supported by Scottish Enterprise, Foresight WAE Technology, SIS Ventures, Ascension, and Conduit EIS Impact Fund.
The company intends to use the funds to accelerate the development of inhaled drugs for patients with respiratory disorders.
Led by Dr Elijah Nazarzadeh (CEO) and Dr John Pritchard (Chair), Nebu-Flow is developing a new generation of nebulisers to enable inhalation delivery of life-changing treatments.
Commenting on the news, Elijah Nazarzadeh said: “Our mission is to revolutionize respiratory drug delivery. The investment accelerates our development activities to position the company for inhalation delivery of RNA-based formulations. We now look forward to the final product development and commercialization stages, with the support of SCVC and our other investors.”
FinSMEs
29/04/2024